Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine

Summary

The primary objectives of this trial are to provide FTC-203 study participants in South Africa with continued access to the study drug, emtricitabine (FTC), following completion of the FTC-203 study and to collect long-term safety information in participants receiving emtricitabine in combination with other antiretroviral agents.

Timeline

Start

2005-11-22

Primary completion

2017-02-13

Completion

2017-02-13

Drugs

Indications